Document is current
Any future updates will be listed below
-
Authors
Raval, Amit D. https://orcid.org/0000-0001-8265-8612
Zhang, Yiqiao
Korn, Matthew
Constantinovici, Niculae
McKay, Rana R. https://orcid.org/0000-0002-0581-7963
-
Funding
Funding for this research was provided by:
Bayer AG
- License Information
-
More Information
Article History
Received: 24 September 2024
Revised: 12 March 2025
Accepted: 25 March 2025
First Online: 4 April 2025
Competing interests
: AR, YZ, MK and NC are employees and stockholders of Bayer. RM reports consulting fees for Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Eisai, Exelixis, Johnson & Johnson, Lilly, Merck, Myovant, NeoMorph, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, Tempus; and institutional research support for Artera, AstraZeneca, Bayer, Tempus, Oncternal, Bristol-Myers Squibb, Exelixis.
